Atossa Therapeutics (NASDAQ: ATOS) deepens Z-endoxifen bet as 2025 losses widen and rare disease optionality grows
EnQuest (LSE: ENQ) full-year 2025 results: Production up 5.4%, dividend raised as South East Asia pivot reshapes growth outlook
Read More 2 minute read General news updates Cash-for-query scandal: Hiranandani speaks up amidst Mahua Moitra controversy In a sensational turn of events, businessman Darshan Hiranandani has come out in the open about the controversial… byPallavi MadhirajuOctober 24, 2023